
#### **APPENDIX 15:**

#### CLINICAL EVIDENCE - FOREST PLOTS


1.1	CASE IDENTIFICATION	2
1.1.1	Sensitivity and specificity for the ASQ/SCQ, AQ (10-, 20-, 21- and 50-item	
versi	ons), PDD-MRS and ABC	2
1.1.2	Sensitivity and specificity for the AQ (-10, -20, -21 and -50) alone at different	nt
	offs	
1.2	ASSESSMENT AND DIAGNOSIS	4
	Sensitivity and specificity for the AAA, ADI and ADI-R, ADOS-G, ASD-D.	
ASD:	I, RAADS and RAADS-R	4
1.3	SETTINGS FOR CARE	5
1.3.1		
1.3.2		
1.4	PSYCHOSOCIAL INTERVENTIONS	10
1.4.1	Behavioural therapies aimed at communication	10
1.4.2		
1.4.3	Cognitive behavioural therapies	11
1.4.4	Leisure programmes	12
1.4.5	Social learning interventions	12
1.4.6	Supported employment programmes	13
1.4.7		
1.5	BIOMEDICAL INTERVENTIONS	16
1.5.1	Antipsychotics	16
1.5.2	Anticonvulsants	22
1.5.3	Drugs affecting cognition	23
1.5.4	Adrenocorticotrophic hormones	24
1.5.5	Secretin	25
1.5.6	Stimulants	25
1.5.7	Antidepressants	26
1.5.8	Restrictive diets, vitamins, minerals and supplements	28

#### 1.1 CASE IDENTIFICATION

## 1.1.1 Sensitivity and specificity for the ASQ/SCQ, AQ (10-, 20-, 21- and 50-item versions), PDD-MRS and ABC




## 1.1.2 Sensitivity and specificity for the AQ (-10, -20, -21 and -50) alone at different cut-offs



#### 1.2 ASSESSMENT AND DIAGNOSIS


## 1.2.1 Sensitivity and specificity for the AAA, ADI and ADI-R, ADOS-G, ASD-DA, ASDI, RAADS and RAADS-R



#### 1.3 SETTINGS FOR CARE


#### 1.3.1 Community-based teams

Current living training environment compared with developmental centre group home training environment for teaching community living skills to adults with a learning disability




#### 1.3.2 Residential accommodation and related services


Community housing compared with residential institution for adaptive behaviour in adults with a learning disability



## Community housing compared with residential institution for residential satisfaction (total score) in adults with a learning disability




### Community housing compared with residential institution for residential satisfaction with social life in adults with a learning disability




## Community housing compared with residential institution for residential satisfaction with autonomy in adults with a learning disability

	Residenti	Residential instituion				ity		Mean Difference	Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	:1	IV, F	ixed	, 95% CI	
BARLOW1991	13.9	1.1	14	15.1	1.8	15	100.0%	-1.20 [-2.28, -0.12]					
Total (95% CI)			14			15	100.0%	-1.20 [-2.28, -0.12]			•		
Heterogeneity: Not app Test for overall effect: 2		0.03)							-20 Favo	-10 ours commun	onity	10 Favours inst	20 titution


### Community housing compared with residential institution for social skills in adults with a learning disability




## Community housing compared with residential institution for social inclusion of adults with a learning disability




### Community housing compared with residential institution for social inclusion of adults with a learning disability




## Community housing compared with residential institution for quality of life of adults with a learning disability




## Small residential homes compared with an institution for quality of life of adults with a learning disability




## Small residential homes compared with an institution for choice making of adults with a learning disability




### Small residential homes compared with an institution for community inclusion of adults with a learning disability




### Small residential homes compared with an institution for family contact of adults with a learning disability




## Dispersed supported housing compared with residential homes for social inclusion of adults with a learning disability



## Semi-independent apartments compared with group homes for resident satisfaction of adults with a learning disability



### Intermediate care placement compared with direct community placement for adaptive behaviour of adults with a learning disability




#### Person-centred planning compared with system-centred planning for movement into the community of adults with a learning disability



#### 1.4 PSYCHOSOCIAL INTERVENTIONS


#### 1.4.1 Behavioural therapies aimed at communication

Natural language teaching compared with analogue language teaching for communication in adults with autism




#### 1.4.2 Behavioural therapies aimed at behaviour management

Independence training compared with no-treatment control group for activities of daily living (showering) in adults with a learning disability




Behavioural weight control programme compared with no-treatment control for self-care (weight loss) in adults with a learning disability



#### 1.4.3 Cognitive behavioural therapies

Cognitive behavioural therapies compared with treatment as usual for severity of coexisting OCD symptoms in adults with autism




#### Anti-victimisation interventions compared with waitlist control for antivictimisation skills (continuous measure) in adults with a learning disability

	Ехре	Experimental Mean SD Total Mea			ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
KHEMKA2000	7.17	1.27	12	3.58	1.56	12	19.9%	2.44 [1.34, 3.54]	<del></del>
KHEMKA2005	3.5	1.62	18	1.83	1.58	18	49.2%	1.02 [0.32, 1.72]	<del></del>
MAZZUCCHELLI2001	28.6	11.7	10	25.3	10.9	10	30.9%	0.28 [-0.60, 1.16]	<del>-</del>
Total (95% CI)			40			40	100.0%	1.07 [0.58, 1.56]	•
Heterogeneity: Chi <sup>2</sup> = 9.04, df = 2 (P = 0.01); $I^2$ = 78% Test for overall effect: Z = 4.29 (P < 0.0001)									-4 -2 0 2 4 Favours control Favours experimental

#### Anti-victimisation interventions compared with waitlist control for antivictimisation skills (dichotomous measure) in adults with a learning disability

	Experim	ental	Conti	rol		Risk Ratio		R	isk Rati	0	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	<u> </u>	M-H,	Fixed, 9	5% CI	
MCGRATH2010	5	20	7	18	100.0%	0.64 [0.25, 1.67]		_			
Total (95% CI)		20		18	100.0%	0.64 [0.25, 1.67]		<			
Total events	5		7								
Heterogeneity: Not ap	plicable						0.01	0.1	+	10	100
Test for overall effect:	Z = 0.91 (P	= 0.36)				Fa		experimen	tal Fav		

### Anger management compared with treatment as usual or waitlist control for anger in adults with a learning disability




#### 1.4.4 Leisure programmes

#### Leisure programmes compared with waitlist control for quality of life in adults with autism


	Expe	erimen	tal	C	ontrol			Mean Difference		Mea	n Differ	ence	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, F	ixed, 9	5% CI	
GARCIAVILLAMISAR2010	63.62	8.99	37	55.29	3.45	34	100.0%	8.33 [5.21, 11.45]				-	
Total (95% CI)			37			34	100.0%	8.33 [5.21, 11.45]				•	
Heterogeneity: Not applicable Test for overall effect: Z = 5.2		.00001	)						-20 F	-10 -avours con	0 trol Fa	10 avours expe	20 erimental

### Leisure programmes compared with waitlist control for emotion recognition in adults with autism




#### 1.4.5 Social learning interventions


## Emotion recognition training compared with treatment as usual for emotion recognition in adults with autism



#### Social skills group interventions compared with waitlist control for social interaction in adolescents with autism




### Social skills group interventions compared with treatment as usual for maladaptive behaviour in adults with a learning disability




#### 1.4.6 Supported employment programmes


### Supported employment programmes compared with sheltered workshop programmes for autistic behaviours in adults with autism




## Supported employment programmes compared with sheltered workshop programmes for quality of life in adults with autism



### Supported employment programmes compared with waitlist control for executive function in adults with autism




### Supported employment programmes compared with treatment as usual for job placements in adults with autism




#### 1.4.7 Support for families, partners and carers

Psychoeducational group permanency planning programme compared with treatment as usual for knowledge and awareness about planning in mothers of adults with a learning disability



# Psychoeducational group permanency planning programme compared with treatment as usual for competence and confidence to plan in mothers of adults with a learning disability




# Psychoeducational group permanency planning programme compared with treatment as usual for appraisals of the planning process by mothers of adults with a learning disability

			Experimental	Control		Std. Mean Difference		Std. Mea	n Diff	erence	
Study or Subgroup	Std. Mean Difference	SE	Total	Total	Weight	IV, Fixed, 95% Cl	I	IV, Fix	ed, 9	5% CI	
BOTSFORD2004	-0.61264	0.394084	13	14	100.0%	-0.61 [-1.39, 0.16]		-			
Total (95% CI)			13	14	100.0%	-0.61 [-1.39, 0.16]		◀			
Heterogeneity: Not app Test for overall effect:	1					F	-4 avours e	-2 xperimenta	0 I Fa	2 vours co	4 ontrol

# Psychoeducational group permanency planning programme compared with treatment as usual for intermediate planning behaviours of mothers of adults with a learning disability

			Experimental	Control		Std. Mean Difference		Std. Me	ean Diff	erence	
Study or Subgroup	Std. Mean Difference	SE	Total	Total	Weight	IV, Fixed, 95% CI		IV, F	ixed, 9	5% CI	
BOTSFORD2004	-0.4872	0.390829	13	14	100.0%	-0.49 [-1.25, 0.28]		-			
Total (95% CI)			13	14	100.0%	-0.49 [-1.25, 0.28]		•			
Heterogeneity: Not app Test for overall effect:						F	-4 avours e	-2 xperimen	0 tal Fa	2 vours co	4 ntrol

# Psychoeducational group permanency planning programme compared with treatment as usual for residential and legal planning of mothers of adults with a learning disability




#### 1.5 BIOMEDICAL INTERVENTIONS

#### 1.5.1 Antipsychotics


Risperidone compared with placebo for challenging behaviour (irritability and aggression) in adults with autism

		1	Experimental	Control		Std. Mean Difference		Std. Me	an Dif	fference	
Study or Subgroup	Std. Mean Difference	SE	Total	Total	Weight	IV, Fixed, 95% CI		IV, Fi	xed, 9	95% CI	
HELLINGS2006	-0.64	0.34949	18	17	54.1%	-0.64 [-1.32, 0.04]		-			
MCDOUGLE1998	-0.96168	0.379583	15	16	45.9%	-0.96 [-1.71, -0.22]		-	-		
Total (95% CI)			33	33	100.0%	-0.79 [-1.29, -0.28]		4	<b>&gt;</b>		
0 ,	0.39, df = 1 (P = 0.53); l <sup>2</sup>	= 0%					-4	<del>-2</del>	0	1 2	4
Test for overall effect:	Z = 3.06 (P = 0.002)					Fa	avours ex	periment	al Fa	avours co	ontrol


### Risperidone compared with placebo for core symptoms of autism (repetitive behaviour) in adults with autism




#### Risperidone compared with placebo for autistic behaviours in adults with autism



### Risperidone compared with placebo for symptom severity or improvement in adults with autism



## Risperidone compared with placebo for challenging behaviour in adults with a learning disability




## Risperidone compared with placebo for aggression in adults with a learning disability

	Experimental SD Tot			(	Control			Mean Difference		Mea	n Differe	nce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95%	CI	IV, F	ixed, 95°	% CI	
TYRER2008	9.08	11.339	29	8.5	9.921	29	100.0%	0.58 [-4.90, 6.06	5]	-		_	
Total (95% CI)			29			29	100.0%	0.58 [-4.90, 6.06	1 .		<b>*</b>	-	
Heterogeneity: Not ap Test for overall effect:			4)						-20 Favours	-10 experimer	0 ntal Fav	10 ours contro	20 ol


### Risperidone compared with placebo for symptom severity or improvement in adults with a learning disability

			Experimental	Control		Std. Mean Difference		Std. Me	ean Diff	ference	
Study or Subgroup	Std. Mean Difference	SE	Total	Total	Weight	IV, Fixed, 95% CI		IV, F	ixed, 9	5% CI	
GAGIANO2005	-0.45938	0.235542	37	37	55.4%	-0.46 [-0.92, 0.00]			-		
TYRER2008	-0.1	0.262755	29	29	44.6%	-0.10 [-0.61, 0.41]			-		
Total (95% CI)			66	66	100.0%	-0.30 [-0.64, 0.04]			•		
Heterogeneity: Chi <sup>2</sup> = Test for overall effect:	1.04, df = 1 (P = 0.31); l <sup>2</sup> Z = 1.71 (P = 0.09)	= 4%				F	-4 avours e	-2 operimen	0 tal Fa	2 vours co	4 ontrol


## Risperidone compared with placebo for quality of life in adults with a learning disability




#### Haloperidol compared with placebo for autistic behaviours in adolescents with autism




#### Haloperidol compared with placebo for side effects (global) in adolescents with autism




## Haloperidol compared with placebo for challenging behaviour in adults with a learning disability



## Haloperidol compared with placebo for aggression in adults with a learning disability




### Haloperidol compared with placebo for symptom severity or improvement in adults with a learning disability




### Haloperidol compared with placebo for quality of life in adults with a learning disability

	Experimental Control							Mean Difference		Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95%	CI	IV,	Fixed, 95	% CI		
TYRER2008	68.33	10.87	28	70.2	10.316	29	100.0%	-1.87 [-7.38, 3.64	1]	_				
Total (95% CI)			28			29	100.0%	-1.87 [-7.38, 3.64	]	•				
Heterogeneity: Not ap Test for overall effect:		(P = 0.	51)						-20 Favours	-10 s experime	0 ntal Fav	10 ours contro	20 ol	

## Risperidone compared with haloperidol for challenging behaviour in adults with a learning disability




## Risperidone compared with haloperidol for aggression in adults with a learning disability




## Risperidone compared with haloperidol for symptom severity or improvement in adults with a learning disability

	Experimental			(	Control			Mean Difference		Mea	an Differe	nce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV,	Fixed, 95%	6 CI	
TYRER2008	3.31	1.436	29	2.58	1.206	28	100.0%	0.73 [0.04, 1.42]					
Total (95% CI)			29			28	100.0%	0.73 [0.04, 1.42]			<b>♦</b>		
Heterogeneity: Not ap Test for overall effect:		(P = 0.	04)						-20 Favo	-10 urs risperido	0 one Favo	10 ours halope	20 eridol


## Risperidone compared with haloperidol for quality of life in adults with a learning disability




## Zuclopenthixol compared with placebo for challenging behaviour (aggression; endpoint data) in adults with a learning disability




## Zuclopenthixol compared with placebo for challenging behaviour (irritability; change from baseline data) in adults with a learning disability




### Zuclopenthixol compared with placebo for symptom severity or improvement (endpoint data) in adults with a learning disability




## Zuclopenthixol compared with placebo for symptom severity or improvement (change from baseline data) in adults with a learning disability



### Prothipendyl compared with placebo for symptom severity or improvement in adults with a learning disability



## Cis(z)-clopenthixol compared with haloperidol for symptom severity or improvement in adults with a learning disability



## Cis(z)-clopenthixol (cis(z)-CPT) compared with haloperidol for side effects in adults with a learning disability


	Experim	ental	Contr	ol		Risk Ratio	Risk Ratio					
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fix	ed, 95% CI				
KARSTEN1981	33	49	39	49	100.0%	0.85 [0.66, 1.08]						
Total (95% CI)		49		49	100.0%	0.85 [0.66, 1.08]						
Total events	33		39									
Heterogeneity: Not app	olicable						0.01 0.1	1 10	100			
Test for overall effect:	Z = 1.36 (P	9 = 0.17)					Favours haloperidol					

#### 1.5.2 Anticonvulsants


## Valproate compared with placebo for challenging behaviour (irritability; continuous data) in children with autism

	Ехре	erimen	tal	Control				Std. Mean Difference	e Std. Mean Difference						
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, F	ixed, 95	% CI			
HELLINGS2005	18.17	8.79	16	15.45	10.39	14	53.8%	0.28 [-0.44, 1.00]							
HOLLANDER2010	14.5	6.67	16	17.7	7.94	11	46.2%	-0.43 [-1.21, 0.35]		-	-				
Total (95% CI)			32			25	100.0%	-0.05 [-0.58, 0.48]			•				
Heterogeneity: Chi <sup>2</sup> =		,	,	l <sup>2</sup> = 41 <sup>o</sup>	%				-4	<del>-2</del>		<del></del>	4		
Test for overall effect:	Z = 0.19	(P = 0)	.85)					Fa	Favours experimental Favours cor				ntrol		


## Valproate compared with placebo for challenging behaviour (irritability; dichotomous data) in children with autism




### Valproate compared with placebo for challenging behaviour (aggression) in children with autism



#### Valproate compared with placebo for symptom severity or improvement in children with autism




#### Valproate compared with placebo for side effects in children with autism




#### 1.5.3 Drugs affecting cognition

### Donepezil hydrochloride compared with placebo for autistic behaviours in children with autism




## Amantadine hydrochloride compared with placebo for challenging behaviour (irritability) in children with autism




#### 1.5.4 Adrenocorticotrophic hormones


### ORG 2766 compared with placebo for challenging behaviour (social withdrawal) in children with autism



## ORG 2766 compared with placebo for challenging behaviour (social isolation) in children with autism



### ORG 2766 compared with placebo for symptom severity or improvement in children with autism



#### 1.5.5 Secretin

#### Secretin compared with placebo for core autistic symptoms of socialcommunication difficulties and symbolic behaviour in children with autism

		E	Experimental	Control		Std. Mean Difference		Std. Me	an Diff	erence	
Study or Subgroup	Std. Mean Difference	SE	Total	Total	Weight	IV, Fixed, 95% CI		IV, Fi	xed, 9	5% CI	
DUNNGEIER2000	0.4	1.071429	47	48	5.4%	0.40 [-1.70, 2.50]			₫•		
LEVY2003	-0.32429	0.255664	31	31	94.6%	-0.32 [-0.83, 0.18]					
Total (95% CI)			78	79	100.0%	-0.29 [-0.77, 0.20]					
• ,	0.43, df = 1 (P = 0.51); $I^2$	= 0%					-4	<del>-</del> 2	0	2	4
Test for overall effect:	Z = 1.15 (P = 0.25)					Fa	avours ex	<i>cperiment</i>	al Fa	vours co	ntrol

### Secretin compared with placebo for autistic behaviours in children with autism


			Experimental	Control		Std. Mean Difference		Std. Me	ean Diff	erence	
Study or Subgroup	Std. Mean Difference	SE	Total	Total	Weight	IV, Fixed, 95% C	CI	IV, F	ixed, 95	% CI	
CHEZ2000	-0.15	0.408163	12	12	28.1%	-0.15 [-0.95, 0.65]	]		-		
LEVY2003	-0.28055	0.255247	31	31	71.9%	-0.28 [-0.78, 0.22]	]		4		
Total (95% CI)			43	43	100.0%	-0.24 [-0.67, 0.18]	l				
Heterogeneity: Chi <sup>2</sup> = Test for overall effect:	0.07, df = 1 (P = 0.79); $I^2$ Z = 1.13 (P = 0.26)	= 0%				ı	-4 Favours ex	-2 kperimen	0 tal Fav	2 /ours co	4 ntrol

## Secretin compared with placebo for challenging behaviour in children with autism


		E	xperimental	Control		Std. Mean Difference		Std. M	ean Diff	erence	
Study or Subgroup	Std. Mean Difference	SE	Total	Total	Weight	IV, Fixed, 95% (	CI	IV, F	ixed, 95	5% CI	
LEVY2003	-0.13678	0.254297	31	31	100.0%	-0.14 [-0.64, 0.36	]				
Total (95% CI)			31	31	100.0%	-0.14 [-0.64, 0.36]	l		•		
Heterogeneity: Not ap Test for overall effect:	•						-4 Favours e	-2 xperimer	0 ntal Far	2 vours co	4 ntrol

#### 1.5.6 Stimulants


### Methylphenidate compared with placebo for coexisting hyperactivity in children with autism



### Methylphenidate compared with placebo for the core autistic symptom of social-interaction difficulties in children with autism




## Methylphenidate compared with placebo for the core autistic symptom of repetitive behaviour in children with autism




#### 1.5.7 Antidepressants


#### Clomipramine compared with placebo for autistic behaviours in adolescents with autism



### Clomipramine compared with placebo for global side effects in adolescents with autism



## Fluvoxamine compared with placebo for the core autistic symptom of repetitive behaviour in adults with autism




#### Fluvoxamine compared with placebo for autistic behaviours in adults with autism

		Ex	cperimental	Control		Std. Mean Difference					
Study or Subgroup	Std. Mean Difference	SE	Total	Total	Weight	IV, Fixed, 95% CI		IV, F	ixed, 9	5% CI	
MCDOUGLE1996	-0.81813	0.380117	15	15	100.0%	-0.82 [-1.56, -0.07]		-			
Total (95% CI)			15	15	100.0%	-0.82 [-1.56, -0.07]		<			
Heterogeneity: Not appress for overall effect:	1						-4	-2	0	2	4
rest for overall effect.	2 = 2.13 (1 = 0.03)					F	avours e	xperimen	tal Fa	vours co	ntrol


## Fluvoxamine compared with placebo for the challenging behaviour of aggression (change-from-baseline scores) in adults with autism

			Experimental	Control		Std. Mean Difference		Std. Mea	n Diffe	rence	
Study or Subgroup	Std. Mean Difference	SE	Total	Total	Weight	IV, Fixed, 95% C	i .	IV, Fix	ed, 95%	% CI	
MCDOUGLE1996	-0.92376	0.38413	15	15	100.0%	-0.92 [-1.68, -0.17]		-	-		
Total (95% CI)			15	15	100.0%	-0.92 [-1.68, -0.17]		•	•		
Heterogeneity: Not approved Test for overall effect:							-4	-2	0	2	4
rest for overall effect.	2 - 2.40 (1 = 0.02)					I	Favours e	experimenta	I Favo	ours co	ntrol

## Fluvoxamine compared with placebo for maladaptive behaviour (change-from-baseline scores) in adults with autism



### Fluvoxamine compared with placebo for symptom severity or improvement (dichotomous measure) in adults with autism




### Fluvoxamine compared with placebo for symptom severity or improvement (continuous measure) in adults with autism


			Experimental	Control		Std. Mean Difference		Std.	Mean I	Differe	ence	
Study or Subgroup	Std. Mean Difference	SE	Total	Total	Weight	IV, Fixed, 95% (	CI	IV	, Fixed	l, 95%	CI	
MCDOUGLE1996	-1.9353	0.4424427	15	15	100.0%	-1.94 [-2.80, -1.07	1	-	-			
Total (95% CI)			15	15	100.0%	-1.94 [-2.80, -1.07]	]	•	•			
Heterogeneity: Not ap Test for overall effect:	plicable Z = 4.37 (P < 0.0001)						-4 Favours e	-2 experim	0 ental	Favou	2 urs cor	4 ntrol

#### 1.5.8 Restrictive diets, vitamins, minerals and supplements


Gluten- and casein-free diet compared with treatment as usual for autistic behaviours (social isolation and bizarre behaviour) in children with autism



## Digestive enzyme supplementation compared with placebo for core autistic symptoms (social-communication difficulties) in children with autism




### Digestive enzyme supplementation compared with placebo for challenging behaviour in children with autism




## Digestive enzyme supplementation compared with placebo for gastrointestinal symptoms in children with autism

	Experimental Control					Mean Difference	Mean Difference						
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fixed, 95% CI			
MUNASINGHE2010	4.01	0.68	21	3.87	0.36	22	100.0%	0.14 [-0.19, 0.47]					
Total (95% CI)			21			22	100.0%	0.14 [-0.19, 0.47]			•		
Heterogeneity: Not ap Test for overall effect:	•	· (P = 0	0.40)						-20 F	-10 avours con	0 trol Fav	10 ours expe	20 rimental


### L-carnosine compared with placebo for autistic behaviours in children with autism




### L-carnosine compared with placebo for symptom severity or improvement in children with autism



#### Micronutrients compared with standard medication for autistic behaviours in children with autism



### Micronutrients compared with standard medication for challenging behaviour (irritability) in children with autism



## Micronutrients compared with standard medication for symptom severity or improvement in children with autism

